Cumberland Partners LTD Has Lifted Discovery Comm Srs A (DISCA) Holding By $4.05 Million; Last Week Seres Therapeutics, Inc. (MCRB) Analysts

June 14, 2018 - By Mary Manson

Discovery, Inc. (NASDAQ:DISCA) Logo

Among 9 analysts covering Seres Therapeutics Inc (NASDAQ:MCRB), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics Inc had 26 analyst reports since July 21, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Seres Therapeutics, Inc. (NASDAQ:MCRB) rating on Wednesday, November 8. Cantor Fitzgerald has “Buy” rating and $16.0 target. The company was maintained on Tuesday, March 20 by Oppenheimer. The company was maintained on Wednesday, August 30 by Cantor Fitzgerald. Oppenheimer initiated the stock with “Buy” rating in Thursday, October 12 report. On Thursday, January 11 the stock rating was maintained by Oppenheimer with “Buy”. On Friday, July 29 the stock rating was initiated by H.C. Wainwright with “Buy”. The firm has “Neutral” rating given on Tuesday, July 21 by Goldman Sachs. Canaccord Genuity maintained it with “Buy” rating and $50 target in Tuesday, August 25 report. The firm earned “Buy” rating on Monday, January 25 by H.C. Wainwright. On Monday, June 6 the stock rating was initiated by Cowen & Co with “Outperform”. See Seres Therapeutics, Inc. (NASDAQ:MCRB) latest ratings:

10/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0000 Maintain
20/03/2018 Broker: Oppenheimer Rating: Buy Maintain
08/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
11/01/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0 Maintain

Cumberland Partners Ltd increased Discovery Comm Inc Srs A (DISCA) stake by 58.68% reported in 2018Q1 SEC filing. Cumberland Partners Ltd acquired 192,760 shares as Discovery Comm Inc Srs A (DISCA)’s stock declined 11.24%. The Cumberland Partners Ltd holds 521,260 shares with $11.17 million value, up from 328,500 last quarter. Discovery Comm Inc Srs A now has $18.17B valuation. The stock increased 3.87% or $0.94 during the last trading session, reaching $25.35. About 2.76 million shares traded. Discovery, Inc. (NASDAQ:DISCA) has declined 12.73% since June 14, 2017 and is downtrending. It has underperformed by 25.30% the S&P500. Some Historical DISCA News: ; 21/04/2018 – DJ Discovery Communications Inc Clas, Inst Holders, 1Q 2018 (DISCK); 08/05/2018 – DISCOVERY SEES 2Q U.S. AD GROWTH TO BE UP `LOW SINGLE DIGITS’; 15/05/2018 – Discovery Presenting at JPMorgan Conference Tomorrow; 10/05/2018 – Discovery: Alvarez to Be Chief Accounting Officer With Departure of Kurt Wehner or Dec. 31, Whichever Occurs First; 31/05/2018 – Orange aiming to merge video arm with Altice Studio – Le Figaro; 25/04/2018 – Digital Element Partners with Discovery Inc. to Enhance the Company’s Video Rights Accuracy with Location-Based Technology; 08/05/2018 – Discovery 1Q International Networks Revenue $1.1 Billion; 08/05/2018 – Discovery 1Q Rev $2.31B

More news for Seres Therapeutics, Inc. (NASDAQ:MCRB) were recently published by: Investorplace.com, which released: “3 Cheapest Stocks With Greatest Potential for Growth” on May 29, 2018. Businesswire.com‘s article titled: “Seres Therapeutics to Present at Two Upcoming June Conferences” and published on May 17, 2018 is yet another important article.

The stock increased 0.82% or $0.07 during the last trading session, reaching $8.58. About 57,750 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 12.75% since June 14, 2017 and is downtrending. It has underperformed by 25.32% the S&P500. Some Historical MCRB News: ; 09/05/2018 – SERES THERAPEUTICS INC – QTRLY SHR LOSS $0.69; 17/05/2018 – Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018; 24/05/2018 – Seres Short-Interest Ratio Rises 26% to 56 Days; 10/04/2018 Seres Presenting at Deutsche Bank Health Care Conference May 9; 11/04/2018 – Nestle Health Science US Holdings, Inc., Affiliates Report Stake In Seres Therapeutics; 09/05/2018 – Seres Therapeutics 1Q Loss/Shr 69c; 18/05/2018 – Seres Closes Below 50-Day Moving Average: Technicals; 17/04/2018 – Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at; 17/04/2018 – Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting; 11/04/2018 – NESTLE HEALTH SCIENCE US HOLDINGS, INC REPORTS 16.97 PCT STAKE IN SERES THERAPEUTICS INC AS OF APRIL 10, 2018 – SEC FILING

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $348.80 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

More recent Discovery, Inc. (NASDAQ:DISCA) news were published by: Seekingalpha.com which released: “Discovery announces new Manhattan headquarters” on June 14, 2018. Also Benzinga.com published the news titled: “MKM: Discovery Undervalued Given Growth Potential, Free Cash Flow Outlook” on June 05, 2018. Seekingalpha.com‘s news article titled: “Aftermarket trade ripples run wide from AT&T/Time Warner decision” with publication date: June 12, 2018 was also an interesting one.

Among 35 analysts covering Discovery Communications (NASDAQ:DISCA), 14 have Buy rating, 2 Sell and 19 Hold. Therefore 40% are positive. Discovery Communications had 101 analyst reports since August 3, 2015 according to SRatingsIntel. The company was downgraded on Tuesday, January 9 by Pivotal Research. The firm has “Buy” rating by Citigroup given on Tuesday, August 1. Topeka Capital Markets downgraded Discovery, Inc. (NASDAQ:DISCA) rating on Monday, April 25. Topeka Capital Markets has “Hold” rating and $31 target. The firm has “Hold” rating given on Friday, November 3 by Loop Capital. The firm has “Underperform” rating given on Tuesday, April 26 by Macquarie Research. The company was maintained on Monday, October 16 by KeyBanc Capital Markets. As per Thursday, March 22, the company rating was maintained by Guggenheim. The company was downgraded on Thursday, September 29 by Barrington Research. On Wednesday, February 22 the stock rating was downgraded by Loop Capital to “Hold”. The rating was maintained by Topeka Capital Markets on Monday, December 28 with “Buy”.

Investors sentiment increased to 2.69 in Q1 2018. Its up 1.82, from 0.87 in 2017Q4. It increased, as 42 investors sold DISCA shares while 92 reduced holdings. 123 funds opened positions while 238 raised stakes. 313.69 million shares or 37.15% more from 228.72 million shares in 2017Q4 were reported. Vantage Advsrs Ltd Liability has invested 0% of its portfolio in Discovery, Inc. (NASDAQ:DISCA). Moreover, Tig Advisors Limited Liability Corp has 0.26% invested in Discovery, Inc. (NASDAQ:DISCA). Bluefin Trading Lc invested in 0.53% or 400,888 shares. Psagot Investment House Limited stated it has 500 shares. Swiss Fincl Bank has 977,157 shares for 0.02% of their portfolio. Ancora Advsrs Limited Company invested in 123,543 shares. Meag Munich Ergo Kapitalanlagegesellschaft Mbh reported 61,500 shares. Trexquant Inv Lp holds 0.24% or 176,026 shares. 3,979 are held by Northwestern Mutual Wealth Mgmt. Bessemer Group Inc owns 199 shares. Washington Financial Bank, a Washington-based fund reported 6,791 shares. Quinn Opportunity Prtnrs Lc has 287,145 shares for 0.72% of their portfolio. South Dakota Inv Council invested 0.21% of its portfolio in Discovery, Inc. (NASDAQ:DISCA). Aviva Public Ltd Liability holds 0.02% or 146,774 shares. New York-based Pinnacle Associates has invested 0.79% in Discovery, Inc. (NASDAQ:DISCA).

Since February 28, 2018, it had 2 insider purchases, and 3 selling transactions for $368,338 activity. Another trade for 10,000 shares valued at $212,856 was made by Wiedenfels Gunnar on Wednesday, May 9. The insider Alpert-Romm Adria sold 16,238 shares worth $367,214. Leavy David also sold $484,002 worth of Discovery, Inc. (NASDAQ:DISCA) shares. Sims Savalle sold 2,571 shares worth $61,902. The insider WARGO J DAVID bought 50,000 shares worth $1.07 million.

Cumberland Partners Ltd decreased Royal Bank Of Canada (NYSE:RY) stake by 3,974 shares to 353,207 valued at $27.24 million in 2018Q1. It also reduced Cgi Group Inc. Cls A (NYSE:GIB) stake by 13,459 shares and now owns 458,873 shares. Pembina Pipeline Corp (NYSE:PBA) was reduced too.

Discovery, Inc. (NASDAQ:DISCA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: